JN Biosciences

JN Biosciences is a biotechnology company specializing in the discovery and engineering of therapeutic antibodies for oncology and inflammatory diseases. Based in Santa Clara, California, the company utilizes proprietary platforms for antibody humanization and affinity maturation to develop high-potential drug candidates. Their lead program, a non-mitogenic anti-CD28 antibody, is being developed in collaboration with Teijin Pharma for autoimmune conditions. JN Biosciences also offers its antibody engineering expertise to global pharmaceutical partners through licensing and research collaborations. The company's technology focuses on optimizing the pharmacological and physicochemical properties of monoclonal antibodies to ensure clinical success. The firm was founded by industry veterans with significant experience in antibody design.